PACB vs. QTRX, FLDM, HBIO, LIFE, BLI, BNGO, TMO, A, MTD, and WAT
Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE), Berkeley Lights (BLI), Bionano Genomics (BNGO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), and Waters (WAT).
Pacific Biosciences of California (NASDAQ:PACB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.
Quanterix has lower revenue, but higher earnings than Pacific Biosciences of California. Quanterix is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Pacific Biosciences of California received 178 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 67.32% of users gave Pacific Biosciences of California an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
Quanterix has a net margin of -28.82% compared to Pacific Biosciences of California's net margin of -148.13%. Quanterix's return on equity of -10.39% beat Pacific Biosciences of California's return on equity.
86.5% of Quanterix shares are held by institutional investors. 1.4% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 6.9% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Pacific Biosciences of California presently has a consensus target price of $6.59, indicating a potential upside of 251.52%. Quanterix has a consensus target price of $30.60, indicating a potential upside of 85.23%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than Quanterix.
In the previous week, Pacific Biosciences of California had 4 more articles in the media than Quanterix. MarketBeat recorded 8 mentions for Pacific Biosciences of California and 4 mentions for Quanterix. Quanterix's average media sentiment score of 1.19 beat Pacific Biosciences of California's score of 0.64 indicating that Quanterix is being referred to more favorably in the news media.
Pacific Biosciences of California has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.
Summary
Quanterix beats Pacific Biosciences of California on 11 of the 19 factors compared between the two stocks.
Get Pacific Biosciences of California News Delivered to You Automatically
Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacific Biosciences of California Competitors List
Related Companies and Tools
